source
- Amgen and academic centers discuss FDA pilot to accelerate first-in-human trialsThe U.S. Food and Drug Administration is working with industry and research institutions on a pilot program aimed at speeding first-in-human studies. The effort is intended to counter the rapid tim…
- Bausch + Lomb moves dry-eye eye drop to Phase 3 despite missing primary endpoint in Phase 2Bausch + Lomb reported results of a Phase 2 trial of its dual-action dry-eye eye drop, which combines 5% lifitegrast (the active ingredient in Xiidra) with perfluorohexyloctane (PHFO, sold as Miebo…